In Depth 28 Jun 2022 Protecting our food supply chain with precision fermentation Many nations are experiencing a food security crisis caused by geopolitical conflicts, extreme weather and supply chain disruption. A wave of precision fermentation companies is working to protect from future food price shocks by producing sustainable protein ingredients from microbes rather than traditional farms. The world is facing a protracted food security crisis with the […] June 28, 2022 - 8 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 28 Jun 2022 Time Partners closes £30M venture fund to back life sciences startups Time Partners Limited has announced the final closing of its first advised fund, Time Boost Capital I LP, a £30 million ($36.6 million) genomics venture fund to provide match funding to startups graduating from Illumina Accelerator Cambridge, UK. Since opening in July 2020, Illumina Accelerator Cambridge has launched 13 startups focused on harnessing genomics applications […] June 28, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 28 Jun 2022 Companies unite to bolster diagnostics for cancer and liver disease Two companies set on making improvements for those with lung cancer, non-alcoholic fatty liver disease and breast cancer have partnered in a bid to bolster noninvasive diagnostics for the conditions. IV Bio-holdings (IVBH), a clinical-stage bio-platform company that conceives, creates and scales first-generation precision health solutions that improves the detection, diagnosis and treatment of disease […] June 28, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 28 Jun 2022 Breast cancer drug recommended for approval A cancer drug from AstraZeneca and Daiichi Sankyo called Enhertu, that reduces the risk of disease progression or even death by 72%, has been recommended for approval in the European Union (EU). The drug containing trastuzumab deruxtecan is specifically engineered for patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer treated with […] June 28, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 28 Jun 2022 MRM Health starts pouchitis clinical trial MRM Health, a Belgian clinical-stage biopharmaceutical company, has received regulatory approval from the Federal Agency for Medicines and Health Products (FAMHP) in Belgium to start a phase 2 trial with the novel next-generation optimized consortium therapy, MH002, in patients with pouchitis. MH002 is the first consortium therapy in which key disease-driving mechanisms guide therapeutic microbial […] June 28, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 28 Jun 2022 Trinity, St. James’s and Legend Biotech collaborating on solid tumors Trinity College and St. James’s Hospital Dublin (SJH) in Ireland have entered into a strategic collaboration with Legend Biotech, a global biotechnology company developing, manufacturing and commercializing novel therapies. Together, they will develop 3D models exploring chimeric antigen receptor T-cell (CAR-T) cell therapies in solid tumors. CAR T-cell therapies are customized for each individual patient. […] June 28, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 28 Jun 2022 Eiger BioPharmaceuticals presents liver study data Eiger BioPharmaceuticals, Inc., a commercial-stage biopharma company focused on the development of innovative therapies to treat and cure hepatitis delta virus (HDV) and other serious diseases, has announced data presented at the European Association for the Study of the Liver (EASL) International Liver Congress 2022 that took place June 22-26 in London, U.K. David Cory, […] June 28, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 28 Jun 2022 Micropep raises €8.75M to develop alternative crop-protection products French ag-biotech company Micropep, which develops biological micropeptide-based solutions for agriculture, has completed an €8.75 million ($9.3 million) series A1 financing round. Fall Line Capital led the funding, in addition to existing investors, Supernova Invest, Sofinnova Partners, FMC Ventures and IRDI/SORIDEC. Based in Toulouse, Micropep has developed a technological platform that makes it possible to […] June 28, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 28 Jun 2022 Biogen, citing insurance challenges, shutters one of its Aduhelm studies A company says it was forced to end an observational trial of Alzheimer’s drug, Aduhelm, after a ruling by US federal insurance program, Medicare. Biogen said a recent coverage decision by Medicare has forced it to abandon the trial of the drug after enrolling just 29 participants. The company said it made the decision to […] June 28, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 27 Jun 2022 Chimerix awarded $25.3M Public Health Agency of Canada deal for smallpox drug Biopharma firm Chimerix has announced the Public Health Agency of Canada has awarded the company a contract of up to C$25.3 million (US$32.6 million) to procure TEMBEXA (brincidofovir). Execution of the contract will be the responsibility of Chimerix, as it is expected to substantially occur prior to the close of the pending transaction with Emergent […] June 27, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 27 Jun 2022 OneThree Biotech completes build and optimization of AI model for RSV data Poolbeg Pharma, a clinical stage infectious disease pharmaceutical company, says its artificial intelligence (AI) partner, OneThree Biotech, Inc., has completed the build and optimization of a tailored AI model of Poolbeg’s respiratory syncytial virus (RSV) human challenge data and can now commence its analysis. Results are expected in Q4 2022. The tailored AI model is […] June 27, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 27 Jun 2022 Eye inflammation leads to FDA partial clinical hold on Nuvation Bio solid tumor study U.S. biopharma company Nuvation Bio Inc. says the Food and Drug Administration (FDA) has placed a partial clinical hold on the company’s phase 1 dose escalation study of NUV-422 in solid tumors, including high grade glioma, HR+/HER2- advanced breast cancer and metastatic castration resistant prostate cancer. The company’s Phase 1 trial began enrolling patients in […] June 27, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email